Sartoclear Dynamics - New Single-Use Harvesting Technology for high Cell Density Cultures
Sartorius Stedim Biotech (SSB) has introduced Sartoclear Dynamics, a clarification system featuring new single-use technology for harvesting mammalian cell cultures with high cell densities.
Continuous improvements in growth media and cell lines have elevated biomass concentrations in bioprocesses. Therefore, these increasingly higher concentrations place growing challenges on the purification process. As body feed filtration has proved to be the best solution to solve similar challenges in related industries, SSB has now developed this robust technology for biotech applications.
Specially designed for cGMP processing, Sartoclear Dynamics consists of prefilled single-use bags containing ultrapure diatomaceous earth (DE) in a choice of 0.5 kg to 10 kg. With a new quick-connect adapter for dust-free powder transfer, DE can be directly mixed into the cell culture fluid. This porous filter aid prevents blockage of the Sartoclear Dynamics filters. As the system maintains a constant ratio of biomass and filter aid, users will benefit from continuous maximum filter performance.
Consistent results, ease of use, tremendous speed and linear scalability are the key characteristics of the Sartoclear Dynamics technology. Used in combination with precipitation, this technology transforms harvesting from a two-stage process into a singlestage operation, saving valuable footprint — and time.
Stefan Schlack, the Senior Vice President of Marketing at SSB, comments: “With Sartoclear Dynamics, we are closing one of the biggest gaps in the single-use product offering. Nowadays, 2000 L is a standard size for single-use bioreactors, but a centrifuge is still required for removing cells from such volumes. This technology now enables a fully single-use process, which brings enormous flexibility to our customers’ facilities. It also eliminates considerable capital investments, which is attractive for newcomers from emerging biotech markets.”
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.